Treatment of Anemia With Darbepoetin Alfa in Heart Failure

Congestive Heart Failure

Volumn 16, Issue 3, 2010, Pages 87-95

  Abraham, William T ^a   Anand, Inder S ^b   Klapholz, Marc ^c   Ponikowski, Piotr ^d   Scarlata, Debra ^e   Wasserman, Scott M ^e   van Veldhuisen, Dirk J ^f  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^d WROCLAW MEDICAL UNIVERSITY   (Poland)

^e AMGEN INC   (United States)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CYANOCOBALAMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FOLIC ACID; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO;

AGED; ANEMIA; ARTICLE; BLOOD LEVEL; CAUSE OF DEATH; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG DOSE TITRATION; DRUG TOLERABILITY; FEMALE; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPERTENSION; KIDNEY FUNCTION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEIZURE;

AGED; ANEMIA; CONFIDENCE INTERVALS; DOUBLE-BLIND METHOD; ERYTHROPOIETIN; FEMALE; GLOMERULAR FILTRATION RATE; HEART FAILURE; HEMATINICS; HOSPITALIZATION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; OHIO; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 77953987350     PISSN: 15275299     EISSN: 17517133     Source Type: Journal    
DOI: 10.1111/j.1751-7133.2010.00142.x     Document Type: Article

References (35)

1. Lindenfeld J. Prevalence of anemia and effects on mortality in patients with heart failure. Am Heart J 2005, 149(3):391-401.
2. Groenveld HF, Januzzi JL, Damman K. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol 2008, 52(10):818-827.
3. Al-Ahmad A, Rand WM, Manjunath G. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2001, 38(4):955-962.
4. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation 2003, 107(2):223-225.
5. Go AS, Yang J, Ackerson LM. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study. Circulation 2006, 113(23):2713-2723.
6. Kosiborod M, Smith GL, Radford MJ. The prognostic importance of anemia in patients with heart failure. Am J Med 2003, 114(2):112-119.
7. Anand IS, Kuskowski MA, Rector TS. Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT. Circulation 2005, 112(8):1121-1127.
8. Silverberg DS, Wexler D, Sheps D. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001, 37(7):1775-1780.
9. Mancini DM, Katz SD, Lang CC. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 2003, 107(2):294-299.
10. Palazzuoli A, Silverberg D, Iovine F. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J 2006, 152(6):1099-1015. 1096e
11. van der Meer P, Voors AA, Lipsic E. Erythropoietin in cardiovascular diseases. Eur Heart J 2004, 25(4):285-291.
12. Bohlius J, Wilson J, Seidenfeld J. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006, 98(10):708-714.
13. Drueke TB, Locatelli F, Clyne N. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006, 355(20):2071-2084.
14. Singh AK, Szczech L, Tang KL. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006, 355(20):2085-2098.
15. Phrommintikul A, Haas SJ, Elsik M. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007, 369(9559):381-388.
16. Besarab A, Bolton WK, Browne JK. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998, 339(9):584-590.
17. Bennett CL, Silver SM, Djulbegovic B. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008, 299(8):914-924.
18. Ponikowski P, Anker SD, Szachniewicz J. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2007, 49(7):753-762.
19. Ghali JK, Anand IS, Abraham WT. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation 2008, 117(4):526-535.
20. van Veldhuisen DJ, Dickstein K, Cohen-Solal A. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur Heart J 2007, 28(18):2208-2216.
21. van der Meer P, Groenveld H, Januzzi JL. Erythropoietin treatment in patients with chronic heart failure: a meta-analysis. Heart 2009, 95(16):1309-1314.
22. Collins AJ, Li S, St Peter W. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 2001, 12(11):2465-2473.
23. Li S, Collins AJ. Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients. Kidney Int 2004, 65:626-633.
24. Li S, Foley RN, Collins AJ. Anemia, hospitalization, and mortality in patients receiving peritoneal dialysis in the United States. Kidney Int 2004, 65(5):1864-1869.
25. Locatelli F, Pisoni RL, Combe C. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004, 19(1):121-132.
26. Ofsthun N, Labrecque J, Lacson E. The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int 2003, 63(5):1908-1914.
27. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007, 50(3):471-530.
28. Hogenhuis J, Voors AA, Jaarsma T. Anaemia and renal dysfunction are independently associated with BNP and NT-proBNP levels in patients with heart failure. Eur J Heart Fail. 2007, 9(8):787-794.
29. Dickstein K, Cohen-Solal A, Filippatos G. Guidelines for the diagnosis and Treatment of Acute and Chronic Heart Failure 2008. Eur J Heart Fail. 2008, 10:933-989.
30. Kazory A, Ross EA. Anemia: the point of convergence or divergence for kidney disease and heart failure? J Am Coll Cardiol 2009, 53(8):639-647.
31. Palazzuoli A, Silverberg DS, Iovine F. Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. Am Heart J 2007, 154(4):645.e9-e15.
32. Corwin HL, Gettinger A, Fabian TC. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 2007, 357(10):965-976.
33. Timmer SA, De Boer K, Knaapen P. The potential role of erythropoietin in chronic heart failure: from the correction of anemia to improved perfusion and reduced apoptosis? J Card Fail. 2009, 15(4):353-361.
34. McMurray JJV, Anand IS, Maggioni AP. Design of the reduction of events with Darbepoetin alfa in Heart Failure (RED-HF): a phase iii, anaemia-correction, morbidity-mortality trial. Eur J Heart Fail. 2009, 11(8):795-801.
35. van Veldhuisen DJ, McMurray JJ. Are erythropoietin stimulating proteins safe and efficacious in heart failure? Why we need an adequately powered randomised outcome trial. Eur J Heart Fail. 2007, 9(2):110-112.